Eli Lilly and (NYSE:LLY – Get Rating) had its price objective boosted by analysts at Morgan Stanley from $265.00 to $364.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price objective points to a potential upside of 22.66% from the company’s previous close.
LLY has been the subject of a number of other reports. Berenberg Bank upped their price objective on shares of Eli Lilly and from $270.00 to $305.00 and gave the company a “buy” rating in a research note on Monday, December 20th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and from $270.00 to $280.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 4th. BMO Capital Markets upped their price objective on shares of Eli Lilly and from $311.00 to $320.00 and gave the company an “outperform” rating in a research note on Thursday, December 16th. Daiwa Capital Markets assumed coverage on shares of Eli Lilly and in a research note on Thursday, March 10th. They set an “outperform” rating and a $286.00 price objective for the company. Finally, Mizuho dropped their target price on Eli Lilly and from $302.00 to $293.00 and set a “buy” rating on the stock in a report on Friday, February 4th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $295.83.
NYSE LLY traded up $4.26 on Wednesday, reaching $296.75. The company’s stock had a trading volume of 26,357 shares, compared to its average volume of 3,078,677. Eli Lilly and has a twelve month low of $178.58 and a twelve month high of $295.83. The company has a debt-to-equity ratio of 1.68, a quick ratio of 0.97 and a current ratio of 1.23. The stock has a market cap of $282.61 billion, a PE ratio of 48.33, a PEG ratio of 2.36 and a beta of 0.43. The firm’s 50 day moving average is $261.49 and its two-hundred day moving average is $254.74.
Eli Lilly and (NYSE:LLY – Get Rating) last issued its quarterly earnings results on Thursday, February 3rd. The company reported $2.49 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.51 by ($0.02). Eli Lilly and had a net margin of 19.71% and a return on equity of 96.36%. The business had revenue of $8 billion during the quarter, compared to analyst estimates of $7.89 billion. During the same period in the previous year, the company posted $2.75 earnings per share. Eli Lilly and’s revenue was up 7.5% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and will post 8.71 EPS for the current fiscal year.
In other news, CAO Donald A. Zakrowski sold 1,660 shares of the business’s stock in a transaction on Friday, February 25th. The shares were sold at an average price of $243.84, for a total value of $404,774.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $283.80, for a total transaction of $62,436,000.00. The disclosure for this sale can be found here. Insiders sold 897,655 shares of company stock valued at $249,126,932 in the last ninety days. Insiders own 0.12% of the company’s stock.
A number of large investors have recently made changes to their positions in LLY. Vestmark Advisory Solutions Inc. grew its stake in shares of Eli Lilly and by 3.1% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 12,157 shares of the company’s stock worth $3,358,000 after acquiring an additional 364 shares during the last quarter. Wedbush Securities Inc. grew its position in Eli Lilly and by 110.1% in the 4th quarter. Wedbush Securities Inc. now owns 11,235 shares of the company’s stock worth $3,103,000 after purchasing an additional 5,887 shares during the last quarter. Lincoln National Corp increased its holdings in shares of Eli Lilly and by 4.9% during the 4th quarter. Lincoln National Corp now owns 9,656 shares of the company’s stock worth $2,667,000 after purchasing an additional 455 shares during the period. Cadence Bank NA raised its position in shares of Eli Lilly and by 0.5% during the fourth quarter. Cadence Bank NA now owns 10,690 shares of the company’s stock valued at $2,953,000 after buying an additional 58 shares during the last quarter. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors lifted its stake in shares of Eli Lilly and by 11.0% in the fourth quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 6,038 shares of the company’s stock valued at $1,668,000 after buying an additional 597 shares during the period. Hedge funds and other institutional investors own 82.16% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.